A Phase 4 interventional study of Rimegepant and Placebo in Migraine, sponsored by Pfizer. Completed at 111 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Pfizer · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.
Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 10th largest by enrollment, is one of 8 that started in 2022, is one of 9 in phase 4, and was the 18th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in United States, Israel
Ages 18+
Pfizer · Sites in India
Ages 18+
Pfizer · Sites in United States, Israel
Ages 18+
Medstar Health Research Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 16 · Phase 4 9
First in 2011; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 962 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 618 across the 32 interventional studies. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 32 have an industry lead sponsor. The 8 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
47 studies in Migraine Disorders by Pfizer: 10 open now, 14 under way, 6 of them phase 3. Of 30 finished, 24 (80%) have results posted.
Among the 47 studies in Migraine Disorders by Pfizer, this one is the 15th largest by enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2022, is one of 6 in phase 4, and was the 29th registered.
Pfizer’s Migraine Disorders studies by the year they started, since 2007.
3 of the studies testing rimegepant in Migraine Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07918053Chinese PLA General HospitalA Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals | 2027-06 |
| NCT07667621University of South FloridaA Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing rimegepant in Migraine Disorders, from their registry updates:
Among Pfizer’s 47 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rimegepant
Drug: Placebo
Rimegepant 75 mg Oral Disintegrating Tablet (ODT) taken every other day during Double-blind Treatment (DBT) phase
Matching placebo with every other day dosing during DBT phase
Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12)
A migraine day was defined as any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of migraine days per month were prorated to 28 days.
Time frame: Observation phase (28 days prior to randomization), DBT phase (through Month 3 [Week 1 to 12])
Percentage of Participants With >= 50 Percent (%) Reduction From OP in the Number of Moderate or Severe Migraine Days (MD) Per Month Over the Entire DBT Phase (Weeks 1 to 12)
Moderate or severe MD: a MD of moderate or severe headache pain intensity. MD: any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. Qualified migraine headache: migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of moderate or severe MD per month were prorated to 28 days and derived from data in the on-DBT efficacy analysis period as follows: 28\*(total number of moderate or severe MD through Month 3 \[Weeks 1 to 12\])/(total number of e-diary efficacy data days through Month 3 \[Weeks 1 to 12\]).
Time frame: DBT phase (through Month 3 [Week 1 to 12])
Mean Change From OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of the DBT Phase
A migraine day was defined as any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of migraine days per month were prorated to 28 days.
Time frame: Observation phase (28 days prior to randomization), Week 1 to Week 4 of the DBT phase
Mean Change From OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase
A migraine day was defined as any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of migraine days per month were prorated to 28 days.
Time frame: Observation phase (28 days prior to randomization), Week 9 to Week 12 of the DBT phase
Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Restrictive Role Function Domain Score at Week 12 of the DBT Phase
MSQ version 2.1 was a self-administered, 14-item instrument validated in 3 domains: role function-restrictive (7 items), role function-preventive (4 items), emotional function (3 items). The restrictive role function domain consisted of 7 items that described how migraine limited one's daily social and work-related activities. Each item was scored on a 6-point scale ranging from 1 to 6, where "1: none of the time," "2: a little bit of the time," "3: some of the time," "4: a good bit of the time," "5: most of the time," and "6: all of the time,". Item scores were recoded using (7 - original score). Raw dimension scores for restrictive role function domain were computed as a sum of recoded item scores and rescaled from a 0 to 100 scale such that lower score (0) indicated poor quality of life and higher scores (100) indicated better quality of life.
Time frame: Baseline (Day 1) and Week 12 of the DBT phase
Mean Change From Baseline in the Migraine Interictal Burden Scale (MIBS) Score at Week 12 of the DBT Phase
MIBS was a 4-item self-administered questionnaire that measures: impairment in work or school, impairment in family and social life, difficulty making plans or commitments, and emotional/affective and cognitive distress. Each item was rated on a 6-point scale as: don't know/ not applicable; never; rarely; some of the time; much of the time; most or all of the time. The MIBS score was the weighted sum of the item scores and ranged from 0 to 12. Higher scores indicated a greater impact of headaches on the participant's life between headache attacks.
Time frame: Baseline (Day 1) and Week 12
Number of Participants With Any Adverse Events (AEs) by Worst Intensity in the DBT Phase.
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AE intensity included mild, moderate and severe, where Mild: usually transient and required only minimal treatment or therapeutic intervention. Event did not generally interfere with usual activities of daily living. Moderate: usually alleviated with additional specific therapeutic intervention. Event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to participant. Severe: interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. Participants were counted once in each intensity category based on greatest intensity of unique adverse event preferred terms.
Time frame: DBT Phase: From Day 1 to Week 12
Number of Participants With Any AEs by Worst Intensity in the OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AE intensity included mild, moderate and severe, where Mild: usually transient and required only minimal treatment or therapeutic intervention. Event did not generally interfere with usual activities of daily living. Moderate: usually alleviated with additional specific therapeutic intervention. Event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to participant. Severe: interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. Participants were counted once in each intensity category based on greatest intensity of unique adverse event preferred terms.
Time frame: OLE Phase: From Week 12 to Week 24
Number of Participants With Serious AEs (SAEs) in the DBT Phase
A serious adverse event (SAE) was any event that met any of the following criteria at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the offspring who received rimegepant and other important medical events.
Time frame: DBT Phase: From Day 1 to Week 12
Number of Participants With SAEs in the OLE Phase
A SAE was any event that met any of the following criteria at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the offspring who received rimegepant and other important medical events.
Time frame: OLE Phase: From Week 12 to Week 24
Number of Participants With AEs Leading to Study Drug Discontinuation in the DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. In this outcome measure, participants with AEs leading to discontinuation of study drug were reported.
Time frame: DBT Phase: From Day 1 to Week 12
Number of Participants With AEs Leading to Study Drug Discontinuation in the OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. In this outcome measure, participants with AEs leading to discontinuation of study drug were reported.
Time frame: OLE Phase: From Week 12 to Week 24
Number of Participants With Grade 3 to 4 Laboratory Abnormalities: DBT Phase
Laboratory tests included hematology and serum chemistry. All laboratory tests except glucose were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0, where Grade 3=severe events which require hospitalization or prolongation of hospitalization and Grade 4=life-threatening consequences requiring urgent intervention. Glucose was graded according to Division of Acquired Immune Deficiency Syndrome table for Grading Severity of Adult and Pediatric Adverse Events v2.1. Only those Grade 3 or 4 laboratory tests with non-zero values in any of treatment arms are reported in this outcome measure.
Time frame: DBT Phase: From Day 1 to Week 12
Number of Participants With Grade 3 to 4 Laboratory Abnormalities: OLE Phase
Laboratory tests included hematology and serum chemistry. All laboratory tests except glucose were graded according to NCI CTCAE v5.0, where Grade 3=severe events which require hospitalization or prolongation of hospitalization and Grade 4=life-threatening consequences requiring urgent intervention. Glucose was graded according to Division of Acquired Immune Deficiency Syndrome table for Grading Severity of Adult and Pediatric Adverse Events v2.1. Only those Grade 3 or 4 laboratory tests with non-zero values in any of treatment arms are reported in this outcome measure.
Time frame: OLE Phase: From Week 12 to Week 24
Percentage of Participants With >= 50% Reduction From OP in the Number of Migraine Days Per Month (Regardless of Pain Intensity) Over the Entire DBT Phase (Weeks 1 to 12)
A migraine day was defined as any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of migraine days per month were prorated to 28 days and derived from data in the on-DBT efficacy analysis period as follows: 28\*(total number of migraine days through Month 3 \[Weeks 1 to 12\])/(total number of e-diary efficacy data days through Month 3 \[Weeks 1 to 12\]).
Time frame: DBT phase (through Month 3 [Week 1 to 12])
Mean Number of Acute Migraine-Specific Medication Days Per Month in Each Month and Over the Entire DBT Phase (Weeks 1 to 12)
An acute migraine-specific medication day was defined as any calendar day during which a participant took a migraine-specific acute migraine medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. The number of acute migraine-specific medication days per month were prorated to 28 days.
Time frame: DBT phase Months 1, 2 and 3; overall DBT through Month 3 (Week 1 to 12)
Mean Change From Baseline in MIBS Scores at Weeks 4, 8, and 12 in the DBT Phase
MIBS was a 4-item self-administered questionnaire that measures: impairment in work or school, impairment in family and social life, difficulty making plans or commitments, and emotional/affective and cognitive distress. Each item was rated on a 6-point scale as: don't know/ not applicable; never; rarely; some of the time; much of the time; most or all of the time. The MIBS score was the weighted sum of the item scores and ranged from 0 to 12. Higher scores indicated a greater impact of headaches on the participant's life between headache attacks.
Time frame: DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12
Mean Change From Baseline in MSQ Domain Scores at Weeks 4, 8, and 12 in the DBT Phase
MSQ was a self-administered, 14-item instrument validated in 3 domains: role function-restrictive (7 items), role function-preventive (4 items), emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 to 6, where "1: none of the time," "2: a little bit of the time," "3: some of the time," "4: a good bit of the time," "5: most of the time," and "6: all of the time,". Item scores were recoded using (7 - original score). Raw domain scores are computed as a sum of item responses and rescaled to a 0 to 100 scale such that lower score (0) indicated poor quality of life and higher scores (100) indicated better quality of life.
Time frame: DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12
Mean Change From Baseline in Migraine Functional Impact Questionnaire (MFIQ) Domain Scores in Each Month of the DBT Phase
MFIQ was a 26-item participant-report questionnaire. It is designed to measure the subjective impact of migraine on physical, social, and emotional functioning over 5 domains: physical function (5 items), usual activities (10 items), social function (5 items), emotional function (5 items) and overall impact on usual activities (16 items). Participants responded to items using a 5-point scale assigned scores from 1 to 5, with 5 representing the greatest burden. Each domain score was calculated as the sum of the item responses and rescaled to a 0 to 100 scale, with higher scores representing greater burden. The recall period was the past 7 days.
Time frame: DBT Phase: Baseline (Day 1), Months 1, 2, and 3
Change From Baseline in Work Productivity and Activity Impairment (WPAI) - Migraine Absenteeism Scores at Weeks 4, 8, and 12 in the DBT Phase
The WPAI was a 6-item participant-administered questionnaire used to capture work impairment due to migraine pain. The questions are as follows: Q1 = currently employed (yes/no); Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). The absenteeism score was calculated from Q2 and Q4 for participants who responded "yes" to Q1 and ranged from 0 to 100 with higher score indicating greater impairment and less productivity.
Time frame: DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12
Change From Baseline in WPAI - Migraine Presenteeism Scores at Weeks 4, 8, and 12 in the DBT Phase
The WPAI was a 6-item participant-administered questionnaire used to capture work impairment due to migraine pain. The questions are as follows: Q1 = currently employed (yes/no); Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). The presenteeism score was calculated using Q5 for participants who responded "yes" to Q1 and had Q4\>0 and ranged from 0 to 100 with higher score indicating greater impairment and less productivity.
Time frame: DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12
Change From Baseline in WPAI - Migraine Work Productivity Loss Scores at Weeks 4, 8, and 12 in the DBT Phase
The WPAI was a 6-item participant-administered questionnaire used to capture work impairment due to migraine pain. The questions are as follows: Q1 = currently employed (yes/no); Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). The work productivity loss score was calculated using Q2, Q4, and Q5 for participants who responded "yes" to Q1 and ranged from 0 to 100 with higher score indicating greater impairment and less productivity.
Time frame: DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12
Change From Baseline in WPAI - Migraine Activity Impairment Scores at Weeks 4, 8, and 12 in the DBT Phase
The WPAI was a 6-item participant-administered questionnaire used to capture work impairment due to migraine pain. The questions are as follows: Q1 = currently employed (yes/no); Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). The activity impairment score was calculated using Q6 and ranged from 0 to 100 with higher score indicating greater impairment and less productivity.
Time frame: DBT Phase: Baseline (Day 1), Weeks 4, 8, and 12
Mean Change From Baseline in Patient Global Assessment (PGA) Score in Each Month of the DBT Phase
The PGA scale was a single item assessment that measured the participant's overall assessment of migraine on a 5-point scale as: (1) very good: asymptomatic and no limitation of normal activities; (2) good: mild symptoms and no limitation of normal activities; (3) fair: moderate symptoms and limitation of some normal activities; (4) poor: severe symptoms and inability to carry out most normal activities; (5) very poor: very severe symptoms which are intolerable and inability to carry out all normal activities. Lower scores indicated fewer symptoms and less disability to carry out normal activities.
Time frame: DBT Phase: Baseline (Day 1), Months 1, 2, and 3
| Milestone | Double Blind (DB) Rimegepant/ Open Label (OL) Rimegepant | DB Placebo/ OL Rimegepant |
|---|---|---|
| Started | 330 | 328 |
| Treated | 328 | 324 |
| Completed | 316 | 308 |
| Not completed | 14 | 20 |
| Withdrew: Adverse event | 5 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Non-compliance (with study drug) | 0 | 1 |
| Withdrew: Other | 1 | 2 |
| Withdrew: Protocol violation | 0 | 4 |
| Withdrew: Withdrawal of consent | 7 | 10 |
| Milestone | Double Blind (DB) Rimegepant/ Open Label (OL) Rimegepant | DB Placebo/ OL Rimegepant |
|---|---|---|
| Started | 301 | 294 |
| Completed | 292 | 280 |
| Not completed | 9 | 14 |
| Withdrew: Adverse event | 4 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Non-compliance (with study drug) | 0 | 1 |
| Withdrew: Other | 0 | 3 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal of consent | 3 | 6 |
A migraine day was defined as any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of migraine days per month were prorated to 28 days.
| Migraine Days per month | DB Rimegepant | DB Placebo |
|---|---|---|
| Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) | -2.1 (-2.47 to -1.74) | -0.5 (-0.82 to -0.11) |
Moderate or severe MD: a MD of moderate or severe headache pain intensity. MD: any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. Qualified migraine headache: migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of moderate or severe MD per month were prorated to 28 days and derived from data in the on-DBT efficacy analysis period as follows: 28\*(total number of moderate or severe MD through Month 3 \[Weeks 1 to 12\])/(total number of e-diary efficacy data days through Month 3 \[Weeks 1 to 12\]).
| Percentage of participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Percentage of Participants With >= 50 Percent (%) Reduction From OP in the Number of Moderate or Severe Migraine Days (MD) Per Month Over the Entire DBT Phase (Weeks 1 to 12) | 34.0 (28.8 to 39.1) | 13.8 (10.0 to 17.6) |
A migraine day was defined as any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of migraine days per month were prorated to 28 days.
| Migraine Days per month | DB Rimegepant | DB Placebo |
|---|---|---|
| Mean Change From OP in the Number of Migraine Days Per Month in the First 4 Weeks (Weeks 1 to 4) of the DBT Phase | -1.8 (-2.20 to -1.38) | -0.1 (-0.45 to 0.29) |
A migraine day was defined as any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of migraine days per month were prorated to 28 days.
| Migraine Days per month | DB Rimegepant | DB Placebo |
|---|---|---|
| Mean Change From OP in the Number of Migraine Days Per Month in the Last 4 Weeks (Weeks 9 to 12) of the DBT Phase | -2.3 (-2.72 to -1.85) | -0.9 (-1.32 to -0.39) |
MSQ version 2.1 was a self-administered, 14-item instrument validated in 3 domains: role function-restrictive (7 items), role function-preventive (4 items), emotional function (3 items). The restrictive role function domain consisted of 7 items that described how migraine limited one's daily social and work-related activities. Each item was scored on a 6-point scale ranging from 1 to 6, where "1: none of the time," "2: a little bit of the time," "3: some of the time," "4: a good bit of the time," "5: most of the time," and "6: all of the time,". Item scores were recoded using (7 - original score). Raw dimension scores for restrictive role function domain were computed as a sum of recoded item scores and rescaled from a 0 to 100 scale such that lower score (0) indicated poor quality of life and higher scores (100) indicated better quality of life.
| Units on a scale | DB Rimegepant | DB Placebo |
|---|---|---|
| Mean Change From Baseline in the Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Restrictive Role Function Domain Score at Week 12 of the DBT Phase | 21.1 (18.95 to 23.35) | 14.6 (12.48 to 16.68) |
MIBS was a 4-item self-administered questionnaire that measures: impairment in work or school, impairment in family and social life, difficulty making plans or commitments, and emotional/affective and cognitive distress. Each item was rated on a 6-point scale as: don't know/ not applicable; never; rarely; some of the time; much of the time; most or all of the time. The MIBS score was the weighted sum of the item scores and ranged from 0 to 12. Higher scores indicated a greater impact of headaches on the participant's life between headache attacks.
| Units on a scale | DB Rimegepant | DB Placebo |
|---|---|---|
| Mean Change From Baseline in the Migraine Interictal Burden Scale (MIBS) Score at Week 12 of the DBT Phase | -1.9 (-2.24 to -1.52) | -1.0 (-1.36 to -0.67) |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AE intensity included mild, moderate and severe, where Mild: usually transient and required only minimal treatment or therapeutic intervention. Event did not generally interfere with usual activities of daily living. Moderate: usually alleviated with additional specific therapeutic intervention. Event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to participant. Severe: interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. Participants were counted once in each intensity category based on greatest intensity of unique adverse event preferred terms.
| Participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Any AE | 186 | 178 |
| Mild AE | 132 | 126 |
| Moderate AE | 77 | 65 |
| Severe AE | 5 | 3 |
| Moderate or Severe AE | 80 | 65 |
| Not Reported AE | 7 | 17 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. AE intensity included mild, moderate and severe, where Mild: usually transient and required only minimal treatment or therapeutic intervention. Event did not generally interfere with usual activities of daily living. Moderate: usually alleviated with additional specific therapeutic intervention. Event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to participant. Severe: interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. Participants were counted once in each intensity category based on greatest intensity of unique adverse event preferred terms.
| Participants | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant |
|---|---|---|
| Any AE | 121 | 106 |
| Mild AE | 76 | 71 |
| Moderate AE | 52 | 52 |
| Severe AE | 1 | 2 |
| Moderate or Severe AE | 52 | 53 |
| Not Reported AE | 7 | 6 |
A serious adverse event (SAE) was any event that met any of the following criteria at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the offspring who received rimegepant and other important medical events.
| Participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Number of Participants With Serious AEs (SAEs) in the DBT Phase | 1 | 5 |
A SAE was any event that met any of the following criteria at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect in the offspring who received rimegepant and other important medical events.
| Participants | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant |
|---|---|---|
| Number of Participants With SAEs in the OLE Phase | 2 | 4 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. In this outcome measure, participants with AEs leading to discontinuation of study drug were reported.
| Participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Number of Participants With AEs Leading to Study Drug Discontinuation in the DBT Phase | 6 | 3 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. In this outcome measure, participants with AEs leading to discontinuation of study drug were reported.
| Participants | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant |
|---|---|---|
| Number of Participants With AEs Leading to Study Drug Discontinuation in the OLE Phase | 3 | 3 |
Laboratory tests included hematology and serum chemistry. All laboratory tests except glucose were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0, where Grade 3=severe events which require hospitalization or prolongation of hospitalization and Grade 4=life-threatening consequences requiring urgent intervention. Glucose was graded according to Division of Acquired Immune Deficiency Syndrome table for Grading Severity of Adult and Pediatric Adverse Events v2.1. Only those Grade 3 or 4 laboratory tests with non-zero values in any of treatment arms are reported in this outcome measure.
| Participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Neutrophils, low | 1 | 0 |
| Glucose, high | 1 | 0 |
Laboratory tests included hematology and serum chemistry. All laboratory tests except glucose were graded according to NCI CTCAE v5.0, where Grade 3=severe events which require hospitalization or prolongation of hospitalization and Grade 4=life-threatening consequences requiring urgent intervention. Glucose was graded according to Division of Acquired Immune Deficiency Syndrome table for Grading Severity of Adult and Pediatric Adverse Events v2.1. Only those Grade 3 or 4 laboratory tests with non-zero values in any of treatment arms are reported in this outcome measure.
| Participants | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant |
|---|---|---|
| Platelets, low | 0 | 1 |
| Glucose, high | 0 | 1 |
| Glucose, low | 0 | 1 |
| Sodium, high | 1 | 0 |
A migraine day was defined as any calendar day in which participant (1) had a qualified migraine headache or (2) took acute migraine-specific medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. A qualified migraine headache was defined as a migraine with or without aura, lasting for \>=30 minutes, met criteria: \>=2 of pain features: unilateral location; pulsating quality (throbbing); moderate or severe pain intensity; aggravation by or causing avoidance of routine physical activity (e.g., walking or climbing stairs) or \>=1 of associated symptoms: nausea and/or vomiting; photophobia and phonophobia. Number of migraine days per month were prorated to 28 days and derived from data in the on-DBT efficacy analysis period as follows: 28\*(total number of migraine days through Month 3 \[Weeks 1 to 12\])/(total number of e-diary efficacy data days through Month 3 \[Weeks 1 to 12\]).
| Percentage of participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Percentage of Participants With >= 50% Reduction From OP in the Number of Migraine Days Per Month (Regardless of Pain Intensity) Over the Entire DBT Phase (Weeks 1 to 12) | 27.5 (22.6 to 32.3) | 9.4 (6.2 to 12.6) |
An acute migraine-specific medication day was defined as any calendar day during which a participant took a migraine-specific acute migraine medication (i.e., triptan, ergotamine, lasmiditan, or ubrogepant) to treat headache or aura. The number of acute migraine-specific medication days per month were prorated to 28 days.
| Medication Days per month | DB Rimegepant | DB Placebo |
|---|---|---|
| Month 1: <=4 weeks | 3.3 (2.95 to 3.73) | 4.6 (4.18 to 5.09) |
| Month 2: >4 to <=8 weeks | 3.4 (2.96 to 3.79) | 4.8 (4.30 to 5.25) |
| Month 3: >8 to <=12 weeks | 3.5 (3.06 to 3.88) | 4.4 (3.94 to 4.90) |
| Overall DBT | 3.4 (3.03 to 3.76) | 4.6 (4.18 to 5.04) |
MIBS was a 4-item self-administered questionnaire that measures: impairment in work or school, impairment in family and social life, difficulty making plans or commitments, and emotional/affective and cognitive distress. Each item was rated on a 6-point scale as: don't know/ not applicable; never; rarely; some of the time; much of the time; most or all of the time. The MIBS score was the weighted sum of the item scores and ranged from 0 to 12. Higher scores indicated a greater impact of headaches on the participant's life between headache attacks.
| Units on a scale | DB Rimegepant | DB Placebo |
|---|---|---|
| Week 4 | -1.3 (-1.66 to -1.04) | -0.7 (-1.03 to -0.44) |
| Week 8 | -1.7 (-1.99 to -1.32) | -1.1 (-1.45 to -0.80) |
| Week 12 | -1.9 (-2.24 to -1.52) | -1.0 (-1.36 to -0.67) |
MSQ was a self-administered, 14-item instrument validated in 3 domains: role function-restrictive (7 items), role function-preventive (4 items), emotional function (3 items). Each item was scored on a 6-point scale ranging from 1 to 6, where "1: none of the time," "2: a little bit of the time," "3: some of the time," "4: a good bit of the time," "5: most of the time," and "6: all of the time,". Item scores were recoded using (7 - original score). Raw domain scores are computed as a sum of item responses and rescaled to a 0 to 100 scale such that lower score (0) indicated poor quality of life and higher scores (100) indicated better quality of life.
| Units on a scale | DB Rimegepant | DB Placebo |
|---|---|---|
| Restrictive role function domain score: Week 4 | 18.2 (16.17 to 20.13) | 12.7 (10.89 to 14.49) |
| Restrictive role function domain score: Week 8 | 20.7 (18.67 to 22.81) | 13.8 (11.72 to 15.80) |
| Restrictive role function domain score: Week 12 | 21.1 (18.95 to 23.35) | 14.6 (12.48 to 16.68) |
| Preventive role function domain score: Week 4 | 14.0 (12.17 to 15.87) | 9.1 (7.27 to 10.94) |
| Preventive role function domain score: Week 8 | 16.0 (14.06 to 18.02) | 10.3 (8.39 to 12.26) |
| Preventive role function domain score: Week 12 | 16.0 (13.95 to 18.00) | 10.7 (8.66 to 12.68) |
| Emotional function domain score: Week 4 | 15.4 (13.12 to 17.76) | 10.6 (8.22 to 12.89) |
| Emotional function domain score: Week 8 | 17.1 (14.64 to 19.54) | 11.4 (8.99 to 13.74) |
| Emotional function domain score: Week 12 | 17.1 (14.70 to 19.56) | 11.0 (8.51 to 13.43) |
MFIQ was a 26-item participant-report questionnaire. It is designed to measure the subjective impact of migraine on physical, social, and emotional functioning over 5 domains: physical function (5 items), usual activities (10 items), social function (5 items), emotional function (5 items) and overall impact on usual activities (16 items). Participants responded to items using a 5-point scale assigned scores from 1 to 5, with 5 representing the greatest burden. Each domain score was calculated as the sum of the item responses and rescaled to a 0 to 100 scale, with higher scores representing greater burden. The recall period was the past 7 days.
| Units on a scale | DB Rimegepant | DB Placebo |
|---|---|---|
| Physical function: Month 1 | -15.5 (-17.45 to -13.59) | -8.8 (-10.52 to -7.15) |
| Physical function: Month 2 | -18.0 (-20.16 to -15.90) | -11.3 (-13.29 to -9.26) |
| Physical function: Month 3 | -17.4 (-19.60 to -15.23) | -11.7 (-13.76 to -9.57) |
| Usual activities: Month 1 | -14.8 (-16.58 to -13.03) | -7.3 (-9.00 to -5.56) |
| Usual activities: Month 2 | -15.9 (-17.89 to -13.88) | -9.0 (-11.04 to -6.99) |
| Usual activities: Month 3 | -15.5 (-17.52 to -13.50) | -9.5 (-11.59 to -7.34) |
| Social function: Month 1 | -16.2 (-18.05 to -14.25) | -9.2 (-11.12 to -7.34) |
| Social function: Month 2 | -17.4 (-19.63 to -15.25) | -10.6 (-12.81 to -8.42) |
| Social function: Month 3 | -17.3 (-19.51 to -15.08) | -11.7 (-13.91 to -9.41) |
| Emotional function: Month 1 | -15.4 (-17.54 to -13.28) | -8.9 (-10.91 to -6.88) |
| Emotional function: Month 2 | -15.9 (-18.39 to -13.44) | -10.1 (-12.48 to -7.75) |
| Emotional function: Month 3 | -15.5 (-18.01 to -12.97) | -10.7 (-13.25 to -8.19) |
| Overall impact on usual activities: Month 1 | -16.3 (-18.29 to -14.39) | -9.1 (-10.93 to -7.25) |
| Overall impact on usual activities: Month 2 | -18.4 (-20.53 to -16.23) | -10.1 (-12.31 to -7.87) |
| Overall impact on usual activities: Month 3 | -17.8 (-19.99 to -15.68) | -11.9 (-14.10 to -9.71) |
The WPAI was a 6-item participant-administered questionnaire used to capture work impairment due to migraine pain. The questions are as follows: Q1 = currently employed (yes/no); Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). The absenteeism score was calculated from Q2 and Q4 for participants who responded "yes" to Q1 and ranged from 0 to 100 with higher score indicating greater impairment and less productivity.
| Units on a scale | DB Rimegepant | DB Placebo |
|---|---|---|
| Absenteeism: Week 4 | -3.4 (-5.02 to -1.88) | -2.0 (-4.00 to -0.09) |
| Absenteeism: Week 8 | -4.1 (-6.17 to -2.10) | -2.0 (-3.87 to -0.19) |
| Absenteeism: Week 12 | -3.0 (-4.96 to -0.98) | -1.4 (-3.83 to 0.98) |
The WPAI was a 6-item participant-administered questionnaire used to capture work impairment due to migraine pain. The questions are as follows: Q1 = currently employed (yes/no); Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). The presenteeism score was calculated using Q5 for participants who responded "yes" to Q1 and had Q4\>0 and ranged from 0 to 100 with higher score indicating greater impairment and less productivity.
| Units on a scale | DB Rimegepant | DB Placebo |
|---|---|---|
| Presenteeism: Week 4 | -16.8 (-20.54 to -13.14) | -11.8 (-15.24 to -8.30) |
| Presenteeism: Week 8 | -19.8 (-23.63 to -16.07) | -11.8 (-15.41 to -8.18) |
| Presenteeism: Week 12 | -18.8 (-22.38 to -15.20) | -10.9 (-14.69 to -7.04) |
The WPAI was a 6-item participant-administered questionnaire used to capture work impairment due to migraine pain. The questions are as follows: Q1 = currently employed (yes/no); Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). The work productivity loss score was calculated using Q2, Q4, and Q5 for participants who responded "yes" to Q1 and ranged from 0 to 100 with higher score indicating greater impairment and less productivity.
| Units on a scale | DB Rimegepant | DB Placebo |
|---|---|---|
| Work productivity loss: Week 4 | -17.4 (-21.28 to -13.60) | -11.9 (-15.45 to -8.28) |
| Work productivity loss: Week 8 | -20.8 (-24.83 to -16.74) | -11.9 (-15.59 to -8.12) |
| Work productivity loss: Week 12 | -19.1 (-22.94 to -15.24) | -11.5 (-15.51 to -7.51) |
The WPAI was a 6-item participant-administered questionnaire used to capture work impairment due to migraine pain. The questions are as follows: Q1 = currently employed (yes/no); Q2 = hours missed due to health problems; Q3 = hours missed due to other reasons; Q4 = hours actually worked; Q5 = degree health affected productivity while working (0-10 scale, with higher numbers indicating less productivity); Q6 = degree health affected regular activities (0-10 scale, with higher numbers indicating greater impairment of regular activities). The activity impairment score was calculated using Q6 and ranged from 0 to 100 with higher score indicating greater impairment and less productivity.
| Units on a scale | DB Rimegepant | DB Placebo |
|---|---|---|
| Activity impairment: Week 4 | -18.5 (-21.56 to -15.47) | -14.4 (-17.37 to -11.52) |
| Activity impairment: Week 8 | -23.0 (-26.18 to -19.80) | -15.7 (-18.61 to -12.70) |
| Activity impairment: Week 12 | -21.6 (-24.63 to -18.63) | -14.0 (-17.08 to -10.82) |
The PGA scale was a single item assessment that measured the participant's overall assessment of migraine on a 5-point scale as: (1) very good: asymptomatic and no limitation of normal activities; (2) good: mild symptoms and no limitation of normal activities; (3) fair: moderate symptoms and limitation of some normal activities; (4) poor: severe symptoms and inability to carry out most normal activities; (5) very poor: very severe symptoms which are intolerable and inability to carry out all normal activities. Lower scores indicated fewer symptoms and less disability to carry out normal activities.
| Units on a scale | DB Rimegepant | DB Placebo |
|---|---|---|
| Month 1 | -0.1 (-0.19 to -0.08) | 0.0 (-0.08 to 0.02) |
| Month 2 | -0.2 (-0.22 to -0.10) | 0.0 (-0.11 to 0.01) |
| Month 3 | -0.2 (-0.22 to -0.10) | 0.0 (-0.11 to 0.01) |
Collected over Baseline up to 2 weeks after last visit in the last treatment phase (treatment period for DBT: From Day 1 to Week 12 and for OLE: After Week 12 to Week 24; Follow-up: 2 weeks after last visit in the last treatment phase). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB Rimegepant: DBT Phase | 0/328 (0%) | 1/328 (0.3%) | 43/328 (13.1%) |
| DB Placebo: DBT Phase | 0/324 (0%) | 5/324 (1.5%) | 51/324 (15.7%) |
| DB Rimegepant/ OL Rimegepant: OLE Phase | 0/301 (0%) | 2/301 (0.7%) | 22/301 (7.3%) |
| DB Placebo/ OL Rimegepant: OLE Phase | 0/294 (0%) | 4/294 (1.4%) | 12/294 (4.1%) |
| DB Rimegepant/ OL Rimegepant: Follow-up Phase | 0/308 (0%) | 1/308 (0.3%) | 1/308 (0.3%) |
| DB Placebo/ OL Rimegepant: Follow-up Phase | 0/296 (0%) | 2/296 (0.7%) | 2/296 (0.7%) |
| Event | DB Rimegepant: DBT Phase | DB Placebo: DBT Phase | DB Rimegepant/ OL Rimegepant: OLE Phase | DB Placebo/ OL Rimegepant: OLE Phase | DB Rimegepant/ OL Rimegepant: Follow-up Phase | DB Placebo/ OL Rimegepant: Follow-up Phase |
|---|---|---|---|---|---|---|
| Immune thrombocytopeniaBlood and lymphatic system disorders | 0/328 | 0/324 | 0/301 | 1/294 | 0/308 | 0/296 |
| MeningitisInfections and infestations | 0/328 | 0/324 | 0/301 | 1/294 | 0/308 | 0/296 |
| IIIrd nerve paralysisNervous system disorders | 0/328 | 0/324 | 0/301 | 1/294 | 0/308 | 0/296 |
| MigraineNervous system disorders | 0/328 | 0/324 | 0/301 | 1/294 | 0/308 | 0/296 |
| Pneumonia pneumococcalInfections and infestations | 0/328 | 0/324 | 0/301 | 0/294 | 0/308 | 1/296 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/328 | 0/324 | 0/301 | 0/294 | 0/308 | 1/296 |
| Superficial spreading melanoma stage IINeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/328 | 0/324 | 1/301 | 0/294 | 0/308 | 0/296 |
| Renal colicRenal and urinary disorders | 0/328 | 0/324 | 1/301 | 0/294 | 0/308 | 0/296 |
| ArrhythmiaCardiac disorders | 0/328 | 0/324 | 0/301 | 0/294 | 1/308 | 0/296 |
| AnaemiaBlood and lymphatic system disorders | 0/328 | 1/324 | 0/301 | 0/294 | 0/308 | 0/296 |
| Event | DB Rimegepant: DBT Phase | DB Placebo: DBT Phase | DB Rimegepant/ OL Rimegepant: OLE Phase | DB Placebo/ OL Rimegepant: OLE Phase | DB Rimegepant/ OL Rimegepant: Follow-up Phase | DB Placebo/ OL Rimegepant: Follow-up Phase |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 29/328 | 46/324 | 22/301 | 12/294 | 1/308 | 2/296 |
| Back painMusculoskeletal and connective tissue disorders | 17/328 | 7/324 | 5/301 | 3/294 | 0/308 | 0/296 |
DBT safety analysis set (SAS): enrolled participants who took greater than or equal to (\>=)1 dose of DB study drug (rimegepant or placebo).
| Age, Continuous(Years) | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant | Total |
|---|---|---|---|
| Mean | 42.68 ± 10.50 | 41.98 ± 11.14 | 42.33 ± 10.82 |
| Sex: Female, Male(Participants) | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant | Total |
|---|---|---|---|
| Female | 289 | 272 | 561 |
| Male | 39 | 52 | 91 |
| Ethnicity (NIH/OMB)(Participants) | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 8 |
| Not Hispanic or Latino | 14 | 16 | 30 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 15 | 18 | 33 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
Showing the first 100 of 111 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Nov 2022 to primary completion in Mar 2025, 28 months.
Results were first posted in May 2026, 1 year 1 month after primary completion.
Of 28 industry-sponsored phase 4 interventional studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 28 months is close to that.
Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rimegepant